Sign up for our FREE GI E-Weekly for more coverage like this sent to your inbox!
LT-02 is designed to treat ulcerative colitis by improving the barrier function of the colon through a delayed release formula.
The company intends to move forward with the Phase III trial of LT-02 in ulcerative colitis patients.
More Articles on Gastroenterology:
Olympus Surgical Video System Receives FDA 510(k) Clearance
8 Gastroenterology Devices Receive FDA 510(k) Clearance in March
American Cancer Society Awards Dr. Stephen Meltzer Research Grant
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
